ClinicalTrials.gg
CompletedNCT05753592Updated Nov 5, 2026

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

A Phase 1 interventional study of Part 1; LOU064 (Remibrutinib) and Part 2; LOU064 (Remibrutinib) in Hepatic Impairment, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Hungary. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Updated Nov 5, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This was a Phase 1, open-label study to evaluate the PK, safety, and tolerability after administration of multiple doses of remibrutinib in participants with mild, moderate, or severe hepatic impairment (HI) compared to pooled matched healthy control participants with normal hepatic function.

Read the detailed description

This study was conducted in 2 parts. Part 1 was comprised of participants with mild (Child Pugh A; Group 1) and moderate (Child-Pugh B; Group 2) HI and matched healthy control participants with normal hepatic function (Group 4). Groups 1 and 2 were enrolled in parallel. Part 2 was comprised of participants with severe HI (Child-Pugh C; Group 3) and matched healthy control participants with normal hepatic function (Group 4). Matched healthy control participants (Group 4) were enrolled in parallel to Parts 1 and 2.

Up to 48 male and female participants, aged 18 to 70 years inclusive, were planned to be enrolled, with 8 participants enrolled in each of the mild (Child-Pugh A; Group 1 in Part 1), moderate (Child Pugh B; Group 2 in Part 1), and severe (Child-Pugh C; Group 3 in Part 2) HI groups, and up to 24 participants planned to be enrolled in the matched healthy control group (Group 4 from Parts 1 and 2). Additional participant(s) may have been enrolled if a participant discontinued from the study before completion of the PK assessment to ensure that at least 6 participants in each group completed the scheduled PK assessments. Due to difficulties in enrolling severe HI participants, only 7 severe HI participants were enrolled in this study.

Each study part was comprised of a screening period of up to 28 days (Day -29 to Day -2), a Baseline evaluation on Day -1, and a treatment period including up to 8 days of safety and PK data collection. Participants who met the eligibility criteria at Screening were admitted for Baseline evaluations on Day 1. Baseline safety assessments were performed prior to first dosing of study treatment. Participants were domiciled from Day -1 through Day 8.

All participants received 25 mg remibrutinib b.i.d. orally under fasting conditions on Days 1 and 2, and a morning oral dose of 25 mg remibrutinib on Day 3. PK samples were collected predose on Day 3 and until 72 hours post Day 3 dosing. Throughout the study, safety assessments included physical examinations, electrocardiograms (ECGs), vital signs, clinical laboratory evaluations (hematology, chemistry, urinalysis, and coagulation), and AE/serious adverse event (SAE) monitoring.

The investigator and Novartis conducted a joint interim review of safety and PK data from Part 1 before proceeding to Part 2. Data from at least 4 participants with mild HI (Group 1), 4 participants with moderate HI (Group 2), and their matched healthy control participants (Group 4), who completed PK study assessments up to Day 6 in Part 1, were evaluated.

Part 2 only began after administration of remibrutinib in the 4 evaluable participants from each of the mild and moderate HI groups (Groups 1 and 2) and their matched healthy control participants (Group 4) in Part 1 was deemed safe and tolerable based on the interim review by the investigator and Novartis. Depending on the outcome of the interim review, administration of a lower dose of remibrutinib in severe HI participants (Group 3) and their matched healthy control participants was to be considered. However, upon review of the interim data, the decision was made to not change the dose for severe HI participants.

As per the current study protocol, study drug strengths available for this trial were 25 mg and 10 mg. Therefore, the lowest dose that could have been used in Part 2 was 10 mg b.i.d. At the time of the interim data review, a decision was to be made as to whether or not to reduce the Part 2 dose, based on observed PK exposures and safety assessments in Part 1 and predicted exposures in severe HI participants in Part 2. In this particular case, Part 2 was to be initiated after the submission and approval of a Substantial Amendment from the respective Health Authorities (HA) and Ethics Committee (EC) were obtained. A decision was made to proceed with Part 2 using the same 25 mg dose as in Part 1.

Study Completion evaluations occurred on Day 8, followed by a post-study safety follow-up contact (e.g., follow-up telephone call, e-mail) approximately 30 days after last administration of study treatment. The information collected during the follow-up contact was kept as source documentation. The study was considered completed once all the participants finished the required assessments.

The total study duration for each participant was expected to be up to approximately 62 days, including the Screening period and the follow-up contact.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Remibrutinib (LOU064)
  • Hepatic Impairment (HI)
  • Pharmacokinetic (PK)
  • Safety
  • Tolerability
  • Child-Pugh
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants

  1. Signed was obtained prior to participation in the study.
  2. Male and non- female* participants 18 to 70 years of age, inclusive, at Screening.
  3. Women of non-childbearing potential were defined as women who were post menopausal or had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least 6 weeks prior to first dosing of study treatment. In the case of oophorectomy alone, only when the reproductive status of the woman was confirmed by follow-up hormone level assessment was she considered not of childbearing potential. Women were considered if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms).
  4. Must have been a non-smoker or a light smoker who smoked no more than 10 cigarettes (or equivalent) per day, at Screening. Smokers must have agreed to smoke no more than 5 cigarettes (or equivalent) per day from check-in until after Study Completion evaluations.
  5. Must have been able to communicate well with the investigator and to understand and comply with the requirements of the study.

    Participants with mild, moderate, and severe HI (Groups 1, 2 and 3)

  6. Must have weighed at least 50 kg to participate in the study and must have had a (BMI) within the range of 18.0 to 35.0 kg/m2, inclusive, at Screening.
  7. Seated vital signs must have been within the following ranges at Screening and Baseline:

    • body temperature, 35.0 to 37.5°C, inclusive
    • systolic blood pressure (BP), 90 to 160 mmHg, inclusive
    • diastolic BP, 50 to 100 mmHg, inclusive
    • pulse rate, 50 to 110 bpm, inclusive
  8. Had impaired hepatic function as defined by the classification for severity of liver disease and had a Child-Pugh score in line with one of the following HI groups at Screening:

    • Group 1; mild (Class A); Child-Pugh score 5-6, inclusive
    • Group 2; moderate (Class B); Child-Pugh score 7-9, inclusive
    • Group 3; severe (Class C); Child-Pugh score 10-15, inclusive
  9. Stable Child-Pugh status and no worsening of more than 1 point in Child-Pugh score within 28 days prior to first dosing of study treatment.
  10. Participants with other stable medical disorders such as controlled diabetes, hyperlipidemia, hypothyroidism, etc., may have been eligible as long as they were considered appropriate for enrollment as determined by the investigator by past medical history, physical examination, , and clinical laboratory tests at Screening.

    Healthy control participants (Group 4)

  11. Each healthy participant must have matched the age (±10 years), body weight (±20%), and gender of at least one participant of Group 1 (Part 1), 2 (Part 1), or 3 (Part 2).
  12. Must have weighed at least 50 kg to participate in the study and must have had a BMI within the range of 18.0 to 30.0 kg/m2, inclusive, at Screening.
  13. Must have been in good health as determined by medical history, physical examination, ECG, and clinical laboratory tests at Screening.
  14. Seated vital signs must have been within the following ranges at Screening and Baseline:

    • body temperature, 35.0 to 37.5°C, inclusive
    • systolic BP, 89 to 139 mmHg, inclusive
    • diastolic BP, 50 to 89 mmHg, inclusive
    • pulse rate, 45 to 90 bpm, inclusive

Exclusion criteria

Exclusion Criteria:

All participants

  1. Use of other drugs within 5 half-lives or 30 days prior to first dosing of study treatment, whichever was longer.
  2. History of to the study treatment or its or to drugs of similar chemical classes.
  3. History or presence of of any organ system (other than treated localized basal cell or squamous cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years of Screening, regardless of whether there was evidence of local recurrence or .
  4. History of immunodeficiency diseases or had a positive (HIV) test result at Screening.
  5. History or presence of any ongoing, chronic, or recurrent infectious disease (including tuberculosis, atypical mycobacterioses, listeriosis, aspergillosis).
  6. Female participants who were of , defined as all women physiologically capable of becoming pregnant.
  7. Female participants who were pregnant or nursing (lactating). Pregnancy was defined as the state of a female participant after conception and until termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test at Screening or Baseline.
  8. Use of prohibited prescription or non-prescription medication or supplement.
  9. Received any within 8 weeks prior to first dosing of study treatment.
  10. Received any coronavirus disease-2019 (COVID-19) vaccines within 2 weeks prior to first dosing of study treatment.
  11. Clinical signs and symptoms consistent with COVID-19 (e.g., fever, dry cough, dyspnea, sore throat, fatigue) or confirmed infection by appropriate laboratory test within 2 weeks prior to Screening or tested positive during the Screening period before study site check in.
  12. History or presence of significant bleeding risk or any coagulation disorder.
  13. Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing of study treatment, or longer if required by local regulation.
  14. Any surgical or medical condition which could have significantly altered the absorption, distribution, metabolism or excretion of drugs (apart from cholecystectomy), or which could have jeopardized the participants in case of participation in the study.
  15. History of unhealthy alcohol use within 12 months prior to first dosing of study treatment, or evidence of such abuse as indicated by the laboratory assays (i.e., positive alcohol test) conducted during Screening or Baseline. Note: Participants who did not agree to comply with abstinence from alcohol use from 48 hours prior to first dosing of study treatment until after Study Completion evaluations were excluded. Unhealthy alcohol use was defined as a history of, or current alcohol misuse/abuse, defined as > 21 drinks for males and > 14 drinks for females in the same week.
  16. Positive drug test at Screening or Baseline, unless the positive drug screen was due to prescription drug use that was approved by the investigator and Novartis.
  17. Regular use of caffeine or methyl xanthine-containing products exceeding 800 mg (\~4 cups of coffee containing 200 mg caffeine per cup) per day.

    Participants with mild and moderate HI (Groups 1 and 2)

  18. Abnormal clinical laboratory values for any of the following parameters at Screening or Baseline:

    • \< 9 g/dL
    • count \< 30 × 109/L
    • white blood cell count \< 2.5 × 109/L
    • \< 1.5 × 109/L
    • lymphocytes \< 0.8 × 109/L
    • total (TBL) > 8 mg/dL
    • serum amylase > 2 × (ULN)
    • > 2.3
    • serum ammonia level > 200 μg/dL
    • corrected serum calcium \< 8.6 or > 10.2 mg/dL
  19. Severe complications of liver disease within the preceding 3 months of Screening.
  20. Emergency room visit or hospitalization due to liver disease within the preceding 3 months of Screening.
  21. Received liver transplant at any time in the past and/or was on therapy at Screening.
  22. Required paracentesis more than every 30 days for the management of ascites.
  23. Transjugular intrahepatic portosystemic shunt and/or underwent portacaval shunting.
  24. Acute virus (HBV) or acute virus (HCV) infection. A positive hepatitis B surface antigen (HBsAg) test excluded a participant. Participants with a positive HCV antibody test had HCV ribonucleic acid (RNA) levels measured. Participants with positive (detectable) HCV RNA were excluded.
  25. abnormal findings in physical examination, or clinical laboratory evaluations, not consistent with known liver disease. Participants having had myocardial infarction \< 5 years of Screening were not eligible to participate; participants having had myocardial infarction ≥ 5 years of Screening could have been eligible to participate.
  26. Presence of moderate to severe impaired renal function as indicated by any of the following at Screening:

    • Estimated (eGFR) \< 45 mL/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
    • Serum creatinine > 1.5 × ULN
  27. Encephalopathy Grade 3 or worse within 28 days of planned first dosing of study treatment.
  28. Primary biliary cholangitis or biliary obstruction.
  29. History of gastrointestinal (GI) bleeding within the past 3 months prior to Screening.
  30. Clinically significant illness within 2 weeks prior to first dosing that could have jeopardized safety of the study participant and/or altered the study results as judged by the investigator.

    Participants with severe HI (Group 3)

  31. Abnormal clinical laboratory values for any of the following parameters at Screening or Baseline:

    • hemoglobin \< 8.5 g/dL
    • platelet count \< 30 × 109/L
    • white blood cell count \< 2.5 × 109/L
    • TBL > 8 mg/dL
    • serum amylase > 2 × ULN
    • serum ammonia level > 200 μg/dL
    • INR > 2.3
  32. Severe complications of liver disease within the preceding 3 months of Screening.
  33. Emergency room visit or hospitalization due to liver disease within the preceding 1 month of Screening.
  34. Received liver transplant at any time in the past and/or was on immunosuppressant therapy at Screening.
  35. Required paracentesis more than every 30 days for the management of ascites.
  36. Transjugular intrahepatic portosystemic shunt and/or have undergone portacaval shunting.
  37. Acute HBV or acute HCV infection. A positive HBsAg test excluded a participant. Participants with a positive HCV antibody test had HCV RNA levels measured. Participants with positive (detectable) HCV RNA were excluded.
  38. Clinically significant abnormal findings in physical examination, ECG or clinical laboratory evaluations, not consistent with known liver disease. Participants having had myocardial infarction \< 5 years of Screening were not eligible to participate, participants having had myocardial infarction ≥ 5 years of Screening could have been eligible to participate.
  39. Presence of moderate to severe impaired renal function as indicated by any of the following at Screening:

    • eGFR \< 45 mL/min/1.73 m2 based on the CKD-EPI equation
    • Serum creatinine > 1.5 × ULN
  40. Encephalopathy Grade 3 or worse within 28 days of planned first dosing of study treatment.
  41. Primary biliary cholangitis or biliary obstruction.
  42. History of GI bleeding within the past 3 months prior to Screening.
  43. Documented presence of esophageal varices (Stage 3 or 4) based on the evaluation of the participant's medical history at Screening and Baseline.
  44. History, clinical evidence or suspicion of a hepato-cellular carcinoma (HCC) based on sonographical and/or laboratory results (i.e., α-fetoprotein [AFP] > 12 IU/mL [2 × ULN] at Screening).
  45. Severe ascites and/or pleural effusion.
  46. Participants with clinical evidence of suspected acute liver failure as judged by the investigator.
  47. Clinically significant illness within 2 weeks prior to first dosing that could have jeopardized safety of the study participant and/or altered the study results as judged by the investigator.

    Healthy control participants (Group 4)

  48. Significant illness which had not resolved within 2 weeks prior to first dosing of study treatment.
  49. Liver disease or liver injury as indicated by abnormal liver function tests at Screening. Any single parameter of (ALT), AST, gamma-glutamyltransferase (GGT), or alkaline phosphatase (ALP) exceeding 1.2 × ULN or ≥ 1.5 × ULN TBL OR any elevation above ULN of more than one parameter of ALT, AST, GGT, ALP or TBL.
  50. Known to have Gilbert's syndrome.
  51. Positive result for HBsAg or HCV antibody at Screening.
  52. Hemoglobin levels below 11.0 g/dL for males and 10.0 g/dL for females at Screening or Baseline.
  53. History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or blood urea nitrogen (BUN) and/or urea values, or abnormal urinary constituents at Screening.

In the case where a safety laboratory assessment at Screening or Baseline was outside of the range specified above, the assessment may have been repeated once at Screening and/or once at Baseline. If the repeat value remained outside of the specified ranges, the participant was excluded from the study.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Part 1; LOU064 (Remibrutinib)

    Mild and Moderate HI participants and matching healthy participants

    Drug: Part 1; LOU064 (Remibrutinib)

  • Experimental
    Part 2; LOU064 (Remibrutinib)

    Severe HI participants and matching healthy participants

    Drug: Part 2; LOU064 (Remibrutinib)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss

    The maximum (peak) observed blood concentration following multiple-dose administration (mass/volume)

    Time frame: 72 hours

  2. AUCtau

    The area under the curve (AUC) from time zero to the end of the dosing interval tau (12 hours) following multiple-dose administration

    Time frame: 72 hours

  3. AUClast,ss

    The area under the curve (AUC) from time zero to the last measurable blood concentration sampling time (Tlast) following multiple-dose administration (mass\*time/volume)

    Time frame: 72 hours

  4. Tmax,ss

    The time to reach maximum (peak) blood concentration following multiple-dose administration (time)

    Time frame: 72 hours

  5. T1/2

    The elimination half-life associated with the terminal slope (lambda\_z) of a semi logarithmic concentration-time curve (time)

    Time frame: 72 hours

Secondary outcomes

  1. Number of participants with adverse events

    The distribution of adverse events was done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs), through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: 8 days

  2. Unbound fraction; Cmax,ss,u

    The maximum (peak) observed unbound plasma concentration following multiple-dose administration (mass/volume)

    Time frame: 8 days

  3. Unbound fraction; AUCtau,u

    The unbound plasma AUC from time zero to the end of the dosing interval tau (12 hours) following multiple-dose administration

    Time frame: 8 days

  4. Unbound fraction; AUClast,ss,u

    The area under the curve (AUC) from time zero to the last measurable unbound plasma concentration sampling time (Tlast) following multiple-dose administration (mass\*time/volume)

    Time frame: 8 days

07

Study locations

1 site
  • Novartis Investigative Site
    Miskolc, Baz H-3529, Hungary
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Dec 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Mar 3, 2023
StartActual
Oct 31, 2022
Primary completionActual
Dec 14, 2023
CompletionActual
Dec 17, 2023
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionT1/2: how it is measured was reworded
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionT1/2: how it is measured was reworded
    + 4 other changes: verification date, arm descriptions, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05753592
Responsible party
Sponsor
First posted
Mar 3, 2023
Start date
Oct 31, 2022
Primary completion
Dec 14, 2023
Completion
Dec 17, 2023
Last update
Nov 5, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion